Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging BRAF inhibitors for melanoma.

Expert opinion on emerging drugs - 1 Dec 2013

Sabbatino Francesco, Wang Yangyang, Wang Xinhui, Ferrone Soldano, Ferrone Cristina R

Abstract excerpt

INTRODUCTION: The clinical activity of BRAF inhibitor (BRAF-I) therapy is a major breakthrough in the treatment of metastatic melanoma carrying BRAF mutations. However, the therapeutic efficacy of BRAF-I therapy is limited due to the onset of intrinsic and acquired drug resistance. AREAS COVERED: The role of wild-type BRAF in melanocytes and of the mutated BRAF in the pathogenesis of melanoma is described in this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Combined Modality Therapy
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Discovery

Share to Immunotherapy

Share to MAP Kinase Signaling System

Share to Melanoma

Share to Molecular Targeted Therapy

Source

Identifiers

PMID: 24073999
DOI: 10.1517/14728214.2013.842975

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging BRAF inhibitors for melanoma.PMID 24073999Read ↗

BRAF in melanoma: current strategies and future directions.Semantic proximity Read ↗

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.Semantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

Braf-Mutant Melanomas: Biology and TherapySemantic proximity Read ↗

Emerging insights into resistance to BRAF inhibitors in melanoma.Semantic proximity Read ↗

Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.Semantic proximity Read ↗

Braf-Mutant Melanomas: Biology and Therapy.Semantic proximity Read ↗

Targeting BRAF in melanoma: biological and clinical challenges.Semantic proximity Read ↗

BRAF Inhibitors and MelanomaSemantic proximity Read ↗

Beyond BRAF: where next for melanoma therapy?Semantic proximity Read ↗

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?Semantic proximity Read ↗

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.